Dual aromatase-steroid sulfatase inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 15, 2007, Pages 3540-3560

  Woo, L W Lawrence ^a   Bubert, Christian ^a   Sutcliffe, Oliver B ^a   Smith, Andrew ^a   Chander, Surinder K ^b   Mahon, Mary F ^c   Purohit, Atul ^b   Reed, Michael J ^b   Potter, Barry V L ^a  

^a UNIVERSITY OF BATH   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c University of Bath Claverton Down   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AROMATASE INHIBITOR; DUAL AROMATASE STEROID SULFATASE INHIBITOR; ENZYME INHIBITOR; LETROZOLE; SERIC GONADOTROPIN; STERYL SULFATASE; SULFAMIC ACID 2 BROMO 4 [[(4 CYANOPHENYL)[1,2,4]TRIAZOL 4 YLAMINO]METHYL]PHENYL ESTER; SULFAMIC ACID 5 [[(4 CYANOPHENYL)[1,2,4]TRIAZOL 4 YLAMINO]METHYL] 2 FLUOROPHENYL ESTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; WISTAR RAT; X RAY CRYSTALLOGRAPHY;

ANIMALS; AROMATASE INHIBITORS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS; RATS, WISTAR; STERYL-SULFATASE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRIAZOLES;

EID: 34547595440     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061462b     Document Type: Article

References (86)

1. Wells, S. A.; Santen, R. T.; Lipton, A.; Haagensen, D. E., Jr.; Ruby, E. J.; Harvey, H.; Dilley, W. G. Medical adrenalectomy with aminoglutethimide clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann. Surg. 1978, 187, 475-484.
2. Howell, A.; Dowsett, M. Endocrinology and hormone therapy in breast cancer. Aromatase inhibitors versus antioestrogens. Breast Cancer Res. 2004, 6, 269-274.
3. (a) Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H. P.; Janicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P. P.; Salminen, E.; Snyder, R.; Lassus, M.; Verbeek, J. A.; Staffler, B.; Chaudri-Ross, H. A.; Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group. J. Clin. Oncol. 2001, 19, 2596-2606.
4. (b) Bonneterre, J.; Buzdar, A.; Nabholtz, J. M. A.; Robertson, J. F. R.; Thurlimann, B.; von Euler, M.; Sahmoud, T.; Webster, A.; Steinberg, M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001, 92, 2247-2258.
5. (c) Paridaens, R.; Dirix, L.; Lohrisch, C.; Beex, L.; Nooij, M.; Cameron, D.; Biganzoli, L.; Cufer, T.; Duchatea, L.; Hamilton, A.; Lobelle, J. P.; Piccart, M. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 2003, 14, 1391-1398.
6. (d) Mouridsen, H.; Gershanovick, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H. P.; Jaenicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P. P.; Salminen, E.; Snyder, R.; Chaudri-Ross, H.; Lang, R.; Wyld, P.; Bhatnagar, A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group. J. Clin. Oncol. 2003, 21, 2101-2109.
7. (e) Milla-Santos, A.; Milla, L.; Portella, J.; Rallo, L.; Pons, M.; Rodes, E.; Casanovas, J.; Puig-Gali, M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer. A prospective, randomized, phase III study. Am. J. Clin. Oncol. 2003, 26, 317-322.
8. (f) Nabholtz, J. M.; Bonneterre, J.; Buzdar, A.; Robertson, J. F. R.; Thurlimann, B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer 2003, 39, 1684-1689.
9. (g) Nabholtz, J. M. Advanced breast cancer updates on anastrozole versus tamoxifen. J. Steroid Biochem. Mol. Biol. 2003, 86, 321-325.
10. ATAC Trialists', Group. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment of breast cancer. Lancet 2005, 365, 60-62.
11. The Breast International, Group (BIG) 1-98 Collaborative, Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353, 2747-2757.
12. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.; Potter, B. V. L. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. 2000, 7, 773-791.
13. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Newman, S. P.; Potter, B. V. L. Steroid sulfatase: molecular biology, regulation and inhibition. Endocr. Rev. 2005, 26, 171-202.
14. (a) Noel, C. T.; Reed, M. J.; Jacobs. H. S.; James, V. H. T. The plasma concentration of oestrone sulphate in postmenopausal women: lack of diurnal variation, effect of ovariectomy, age and weight. J. Steroid Biochem. Mol. Biol. 1981, 14, 1101-1105.
15. (b) Tseng, L.; Mazella, J.; Lee, L. U.; Stone, M. L. Oestrogen sulphatase and oestrogen sulphotransferase in human primary mammary carcinoma. J. Steroid Biochem. 1983, 19, 1413-1417.
16. (c) Santner, S. J.; Feil, P. D.; Santen, R. J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance vs. the aromatase pathway. J. Clin. Endocrinol. Metab. 1984, 59, 29-33.
17. (d) James, V. H. T.; McNeill, J. M.; Lai, L. C.; Newton, C. J.; Ghilchik, M. W.; Reed, M. J. (1987). Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987, 50, 269-279.
18. (e) Yamamoto, T.; Kitawaki, J.; Urabe, M.; Honjo, H.; Tamura, T.; Noguchi, T.; Okada, H.; Sasaki, H.; Tada, A.; Terashima, Y.; Nakamura, J.; Yoshihama, M. Estrogen productivity of endometrium and endometrial cancer tissue. Influence of aromatase on proliferation of endometrial cancer cells. J. Steroid Biochem. Mol. Biol. 1993, 44, 463-468.
19. (f) Miller, W. R. Aromatase inhibitors. Where are we now? Br. J. Cancer 1996, 73, 415-417.
20. (g) Bajetta, E.; Zilembo, N.; Bichisao, E.; Martinetti, Q.; Buzzoni, R.; Pozzi, P.; Bidoli, P.; Ferrari, L.; Celio, L. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann. Oncol. 2000, 11, 1017-1022.
21. (a) Adams, J. B.; Garcia, M.; Rochefort, H. Estrogenic effects of physiological concentrations of 5-androstene-3α,17β-diol and its metabolism in MCF-7 human breast cancer cells. Cancer Res. 1981, 41, 4720-4726.
22. (b) Dauvois, S.; Labrie, F. Androstenedione and androst-5-ene-3α, 17β-diol stimulate DMBA-induced mammary tumours. Role of aromatase. Breast Cancer Res. Treat. 1989, 13, 61-69.
23. (c) Naitoh, K.; Honjo, H.; Yamamoto, T.; Urabe, M.; Ogino, Y.; Yasumura, T.; Nambara, T. Oestrone sulphate and sulphatase activity in human breast cancer and endometrial cancer. J. Steroid Biochem. 1989, 33, 1049-1054.
24. (d) Chetrite, G. S.; Cortes-Prieto, J.; Philippe, J. C.; Wright, F.; Pasqualini, J. R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 2000, 72, 23-27.
25. Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Estrone sulfamates, potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 1994, 37, 219-221.
26. (a) Stanway, S. J.; Purohit, A.; Woo, L. W. L.; Sufi, S.; Vigushin, D.; Ward, R.; Wilson, R. H.; Stanczyk, F. Z.; Dobbs, N.; Kulinskaya, E.; Elliott, M.; Potter, B. V. L.; Reed, M. J.; Coombes, R. C. Phase I study of STX64 (667Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12, 1585-1592.
27. (b) Stanway, S. J.; Delavault, P.; Purohit, A.; Woo, L. W. L.; Thurieau, C.; Potter, B. V. L.; Reed, M. J. Steroid Sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 2007, 12, 370-374.
28. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
29. Woo, L. W. L.; Sutcliffe, O. B.; Bubert, C.; Grasso, A.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 2003, 46, 3193-3196.
30. Okada, M.; Yoden, T.; Kawaminami, E.; Shimada, Y.; Kudoh, M.; Isomura, Y.; Shikama, H.; Fujikura, T. Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives. Chem. Pharm. Bull. 1996, 44, 1871-1879.
31. Favia, A. D.; Cavalli, A.; Masetti, M.; Carotti, A.; Recanatini, M. Three-dimensional model of the human aroamtase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 2006, 62, 1074-1087.
32. Hernandez-Guzman, F. G.; Higashiyama, T.; Pangborn, W.; Osawa, Y.; Ghosh, D. Structure of human estrone sulfatase suggests functional roles of membrane association. J. Biol. Chem. 2003, 278, 22989-22997.
33. Hejaz, H. A. M. Ph.D. Thesis, University of Bath, 1998.
34. (a) Kellis, J. T.; Vickery, L. E. Inhibition of human oestrogen synthetase (aromatase) by flavones. Science 1984, 225, 1032-1034.
35. (b) Ibrahim, A. R.; Abdul-Hajj, Y. J. Aromatase inhibition by flavonoids. J. Steroid Biochem. Mol. Biol. 1990, 37, 257-260.
36. (c) Campbell, D. R.; Kurzer, M. S. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J. Steroid Biochem. Mol. Biol. 1993, 46, 381-388.
37. (d) Kao, Y. C.; Zhou, C.; Sherman, M.; Laughton, C. A.; Chen, S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ. Health Perspect. 1998, 106, 85-92.
38. Numazawa, M.; Tominaga, T.; Watari, Y.; Tada, Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids 2006, 71, 371-379.
39. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Potter, B. V. L. The development of steroid sulphatase inhibitors. Endocr.-Relat. Cancer 1996, 3, 9-23.
40. Kelly, S. M. Ferroelectric liquid-crystals. 9. Laterally substituted phenyl benzoates incorporating a trans-1,4-disubstituted cyclohexane ring. Helv. Chim. Acta 1989, 72, 594-607.
41. Narender, N.; Srinivasu, P.; Kulkarni, S. J.; Raghavan, K. V. Regioselective oxyiodination of aromatic compounds using potassium iodide and Oxone. Synth. Commun. 2002, 32, 2319-2324.
42. van Oeveren, A.; Jansen, J. F. G. A.; Feringa, B. L. Enantioselective synthesis of natural dibenzylbutyrolactone lignans (-)-enterolactone, (-)-hinokinin, (-)-pluviatolide, (-)-enterodiol, and furofuran lignan (-)-eudesmin via tandem conjugate addition to γ-alkoxybutenolides. J. Org. Chem. 1994, 59, 5999-6007.
43. Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J. Steroid Biochem. Mol. Biol. 1996, 57, 79-88.
44. Okada, M.; Iwashita, S.; Koizumi, N. Efficient general method for sulfamoylation of a hydroxyl group. Tetrahedron Lett. 2000, 41, 7047-7051.
45. Purohit, A.; Vernon, K. A.; Hummelinck, A. E. W.; Woo, L. W. L.; Hejaz, H. A. M.; Potter, B. V. L.; Reed, M. J. The development of a-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J. Steroid Biochem. Mol. Biol. 1998, 64, 269-275.
46. Hejaz, H. A. M.; Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors or steroid sulfatase. Bioorg. Med. Chem. 2004, 12, 2759-2772.
47. Thakkar, K.; Geahlen, R. L.; Cushman, M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogs of piceatannol. J. Med. Chem. 1993, 36, 2950-2955.
48. Meyers, A. I.; Guiles, J. The asymmetric total synthesis of (+)-reticuline. Heterocycles 1989, 28, 295-301.
49. Buehler, C. A.; Harris, J. O.; Shacklett, C.; Block, B. P. The action of formaldehyde on m-hydroxybenzoic acid. II. J. Am. Chem. Soc. 1946, 68, 574-577.
50. Lloyd, M. D.; Thiyagarajan, N.; Ho, Y. T.; Woo, L. W. L.; Sutcliffe, O. B.; Purohit, A.; Reed, M. J.; Acharya, K. R.; Potter, B. V. L. First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochemistry 2005, 44, 6858-6866.
51. Woo, L. W. L.; Howarth, N. M.; Purohit, A.; Hejaz, H. A. M.; Reed, M. J.; Potter, B. V. L. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. 1998, 41, 1068-1083.
52. Woo, L. W. L.; Purohit, A.; Malini, B.; Reed, M. J.; Potter, B. V. L. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. 2000, 7, 773-791.
53. Reed, J. E.; Woo, L. W. L.; Robinson, J. J.; Leblond, B.; Leese, M. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. 2004, 217, 169-175.
54. Chander, S. K.; Purohit, A.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem. Biophys. Res. Commun. 2004, 322, 217-222.
55. Wood, P. M.; Woo, L. W. L.; Humphreys, A.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J. Steroid Biochem. Mol. Biol. 2005, 94, 123-130.
56. Malini, B.; Purohit, A.; Ganeshapillai, D.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. 2000, 75, 253-258.
57. Ho, Y. T.; Purohit, A.; Vicker, N.; Newman, S. P.; Robinson, J. J.; Leese, M. P.; Ganeshapillai, D.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Inhibition of carbonic anhydrase II by steroidal and nonsteroidal sulphamates. Biochem. Biophys. Res. Commun. 2003, 305, 909-914.
58. Vicker, N.; Ho, Y. T.; Robinson, J.; Woo, L. W. L.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg. Med. Chem. Lett. 2003, 13, 863-865.
59. Ireson, C. R.; Chander, S. K.; Purohit, A.; Parish, D. C.; Woo, L. W. L.; Potter, B. V. L.; Reed, M. J. Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667COUMATE and its sequestration into red blood cells in rats. Br. J. Cancer 2004, 91, 1399-1404.
60. Williams, P. A.; Cosme, J.; Ward, A.; Angova, H. C.; Vinkovic, D. M.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424, 464-468.
61. Sybyl 7.1; Tripos Inc. (1699 South Hanley Road, St. Louis, MO, 63144).
62. (a) Jones, G.; Willet, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
63. (b) Jones, G.; Willet, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
64. (c) Nissink, J. W. M.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein-ligand interaction. Proteins 2002, 49, 457-471.
65. (d) Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
66. (e) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
67. Verras, A.; Kuntz, I. D.; de Montellano, P. R. O. Computer-assisted design of selective imidazole inhibitors for cytochrome p450 enzymes. J Med. Chem. 2004, 47, 3572-3579.
68. (a) Allen F. H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr. 2002, B58, 380-388.
69. (b) van de Streek, J. Searching the Cambridge Structural Database for the "best" representative of each unique polymorph. Acta Crystallogr. 2006, B62, 567-579.
70. (c) Orpen, A. G. Applications of the Cambridge Structural Database to molecular inorganic chemistry. Acta Crystallogr. 2002, B58, 398-406.
71. (d) Allen, F. H.; Motherwell, W. D. S. Applications of the Cambridge Structural Database in organic chemistry and crystal chemistry. Acta Crystallogr. 2002, B58, 407-422.
72. (e) Taylor, R. Life science applications of the Cambridge Structural Database. Acta Crystallogr. 2002, D58, 879-888.
73. (f) Bruno, I. J.; Cole, J. C.; Edgington, P. R.; Kessler, M.; Macrae, C. F.; McCabe, P.; Pearson, J.; Taylor, R. New software for searching the Cambridge Structural Database and visualising crystal structures. Acta Crystallogr. 2002, B58, 389-397.
74. (g) Vista. A Program for the Analysis and Display of Data Retrieved from the CSD; Cambridge Crystallographic Data Centre (12 Union Road, Cambridge, England), 1994.
75. Machin, P. J.; Hurst, D. N.; Bradshaw, R. M.; Blaber, L. C.; Burden, D. T.; Fryer, A. D.; Melarange, R. A.; Shivdasani, C. Beta-1-selective adrenoceptor antagonists. 2. 4-Ether-linked phenoxypropanolamines. J. Med. Chem. 1983, 26, 1570-1576.
76. Kelly, S. M. Ferroelectric liquid-crystals. 9. Laterally substituted phenyl benzoates incorporating a trans-1,4-disubstituted cyclohexane ring. Helv. Chim. Acta 1989, 72, 594-607.
77. Raiford, C. L.; Milbery, J. E. Bromination of benzoic esters of some phenolic compounds. J. Am. Chem. Soc. 1934, 56, 2727-2729.
78. Dunning, B.; Dunning, F.; Reid, E. E. A study of some substituted hydroxybenzyl alcohols. J. Am. Chem. Soc. 1936, 58, 1565-1568.
79. Bender, D. M.; Williams, R. M. An efficient synthesis of (S)-m-tyrosine. J. Org. Chem. 1997, 62, 6690-6691.
80. Narender, N.; Srinivasu, P.; Kulkarni, S. J.; Raghavan, K. V. Regioselective oxyiodination of aromatic compounds using potassium iodide and Oxone. Synth. Commun. 2002, 32, 2319-2324.
81. Forbes, B. J. R.; Gordon, G. A. Mechanism and mechanism-based inactivation of 4-hydroxyphenylpyruvate dioxygenase. Bioorg. Chem. 1994, 22, 343-361.
82. Buehler, C. A.; Harris, J. O.; Shacklett, C.; Block, B. P. The action of formaldehyde on m-hydroxybenzoic acid. II. J. Am. Chem. Soc. 1946, 68, 574-577.
83. Faltis, F.; Holzinger, L.; Ita, P.; Schwarz, R. Über biscoclaurin-alkaloide: die konstitution des chondodendrins und des trilobins (On biscoclaurin alkaloids: the constitution of chondodendrins and trilobins). Chem. Ber. 2006, 74, 79-97.
84. Ishida, T.; Wada, K. Total synthesis of (+/-)-diplodialide-A. J. Chem. Soc., Perkin Trans. 1 1979, 323-327.
85. Tafi, A.; Costi, R.; Botta, M.; Di Santo, R.; Corelli, F.; Massa, S.; Ciacci, A.; Manetti, F.; Artico, M. Antifungal agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-Candida activity, and quantitative structure-analysis relationship studies. J. Med. Chem. 2002, 45, 2720-2732.
86. Yang, P. Y.; Zhou, Y. G. The enantioselective total synthesis of alkaloid (-)-galipeine. Tetrahedron: Asymmetry 2004, 15, 1145-1149.